icon-folder.gif   Conference Reports for NATAP  
 
  (IDRW) International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 4-8, 2013; Toronto, ON, Canada Back grey_arrow_rt.gif
 
 
 
Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens
 
 
  Reported by Jules Levin
International Workshop on HIV & Hepatitis
Virus Drug Resistance and Curative Strategies
June 4-8, 2013
Toronto, Canada
 
DP Porter, R Kulkarni, T Fralich, MD Miller, and KL White
Gilead Sciences Inc, Foster City, CA, United States
 
Glasgow/2012: STaR Study: Single-Tablet Regimen
Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in ART-Na´ve Adults Week 48 Results
- (11/16/12)
 
Glasgow/2012 Gilead press release: Gilead 's Complera® Non-Inferior to Atripla® Among Treatment-Na´ve HIV Patients - (11/16/12)

Res1.gif

Res2.gif

Res3.gif

Res4.gif

Res5.gif

Res6.gif

Res7.gif